Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02245490
Other study ID # 527.30
Secondary ID
Status Completed
Phase Phase 4
First received September 18, 2014
Last updated September 18, 2014
Start date January 2003

Study information

Verified date September 2014
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority Italy: The Italian Medicines Agency
Study type Interventional

Clinical Trial Summary

Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date
Est. primary completion date April 2004
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria:

- Male outpatients aged 50-80 years

- LUTS suggestive of BPH

- Medical history: storage symptoms (frequency, urgency) for at least 6 months

- Urinary Chart:

- At least 8 micturitions per 24 hours on average, over the week of the screening period (check urinary chart at Visit 2)

- Urgency (strong desire to void): at least once per 24 hours on average, over the week of the screening period (check urinary chart at Visit 2)

- I-PSS = 13 at randomisation (Visit 3)

- Qmax: > 4 ml/sec at randomisation (Visit 3), with a voiding volume of at least 150 ml

- Prostate Specific Antigen (PSA) < 2.5 ng/ml or between 2.5 and 10 ng/ml, if cancer is ruled out with the usual procedures of each centre (Visit 1; results before Visit 3)

- Written Informed Consent for participation to the study

Exclusion Criteria:

- Patients with a known history or a diagnosis at the time of the screening visit (Visit 1) of the following conditions:

- Urological disturbances

- Medical history of pelvic surgery

- Palpable bladder at the physical examination, or residue urinary volume > 400 ml

- Known neurological bladder disorder

- Bladder neck stenosis

- Urethral stricture

- Bladder or prostatic cancer

- Bladder stone

- Severe diverticulum of the bladder

- Symptomatic urinary tract infection during last month, or recurrent urinary tract infections (more than 2 during last year)

- Haematuria of unknown origin

- Diseases which may affect micturition (i.e., diabetes mellitus)

- Cardiovascular diseases (if they occurred in the last 6 months)

- Myocardial infarction

- Instable angina

- Clinically significant ventricular arrhythmias

- Heart failure (NYHA classes III/IV)

- Orthostatic hypotension

- Cerebral stroke

- Neurological diseases (if their severity might compromise the correct performance of the trial)

- Senile dementia

- Multiple sclerosis

- Parkinson's disease

- Psychiatric disturbances

- Hepatic or renal insufficiency (biochemistry values 15% outside normal lab ranges, being regarded as clinically relevant by the investigator)

- Clinically significant abnormality in the haematological, blood chemistry and urinary values evidenced on the samples taken at the screening visit (Visit 1)

- Patients who are taking or have been taking a-blockers for BPH or for hypertension, or phytotherapy for BPH within the previous 6 weeks

- Patients who were taking or have been taking:

- a-blockers for BPH or for hypertension within the previous 4 weeks

- phytotherapy for BPH or mepartricin within the previous 4 weeks

- finasteride within the previous 6 months

- anticholinergics within the previous 4 weeks

- antidiuretics within the previous 4 weeks

- concomitant drugs which may influence the pharmacodynamic or pharmacokinetic properties of tamsulosin. In particular: a-blockers and mixed a-ß-blockers, a- agonists, anti-cholinergics

- Patients who are or have been taking part in a clinical study within the previous 3 months

- Patients who have had hypersensitivity or allergic reactions to previously prescribed a- blocker(s)

- Patients judged by the investigator to be inappropriate for inclusion in the study

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Tamsulosin HCl controlled release capsules

Matching placebo capsule


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in mean number of micturitions per day As reported in the Urinary Chart Up to 12 weeks after first drug administration No
Secondary Changes in mean number of urgency episodes per day Up to 12 weeks after first drug administration No
Secondary Changes in voided volume per micturition Up to 12 weeks after first drug administration No
Secondary Changes in International Prostate Symptom Score (I-PSS) on storage and voiding sub-scores Up to 12 weeks after first drug administration No
Secondary Changes in Quality of Life in BPH patients with urinary symptoms (QUIBUS) Italian Score QUIBUS Symptom Score (QUISS) -11 on storage and voiding sub-scores Up to 12 weeks after first drug administration No
Secondary Changes in International Index of Erectile Function (IIEF) Up to 12 weeks after first drug administration No
Secondary Changes in Uroflowmetry Up to 12 weeks after first drug administration No
Secondary Changes in Qmax Up to 12 weeks after first drug administration No
Secondary Changes in volume at the first contraction Up to 12 weeks after first drug administration No
Secondary Number of unstable contractions Up to 12 weeks after first drug administration No
Secondary Maximum amplitude of unstable contractions Up to 12 weeks after first drug administration No
Secondary Number of patients with adverse events Up to 12 weeks after first drug administration No
See also
  Status Clinical Trial Phase
Completed NCT02578953 - Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects Phase 1
Terminated NCT02396420 - Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Phase 2
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Not yet recruiting NCT06452927 - EEP in Patients With Urodynamically Proven DU/DA N/A
Completed NCT02947958 - Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia N/A
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT00427882 - Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Phase 4
Completed NCT02244320 - Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin) N/A
Completed NCT01254071 - A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry. Phase 1
Recruiting NCT04108871 - Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men N/A
Recruiting NCT05686525 - Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men With BPH N/A
Completed NCT01957189 - This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples Phase 1
Completed NCT00316732 - Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS N/A
Completed NCT02715401 - PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers Phase 1
Recruiting NCT02278679 - Digital Rectal Exam Proficiency Tool N/A
Completed NCT01376258 - Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database N/A
Completed NCT01482676 - The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction N/A
Completed NCT00822952 - Prostate Mechanical Imager (PMI) Clinical Bridging Study N/A
Completed NCT00527605 - Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH) Phase 3
Terminated NCT00563485 - Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A

External Links